The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.
作者信息
Assche Gert Van
机构信息
Division of Gastroenterology University of Leuven Hospitals Leuven, Belgium.
出版信息
Gastroenterol Hepatol (N Y). 2008 Mar;4(3):197-9.
Abstract
摘要
相似文献
1
The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.
Gastroenterol Hepatol (N Y). 2008 Mar;4(3):197-9.
2
Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
Expert Rev Clin Immunol. 2019 Sep;15(9):969-979. doi: 10.1080/1744666X.2019.1646127. Epub 2019 Jul 25.
3
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.
Inflamm Bowel Dis. 2019 Jul 17;25(8):1417-1427. doi: 10.1093/ibd/izz001.
4
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2020 Jan;18(1):69-81.e3. doi: 10.1016/j.cgh.2019.02.044. Epub 2019 Mar 12.
5
Biologic therapy of inflammatory bowel disease.
Gastroenterology. 2002 May;122(6):1592-608. doi: 10.1053/gast.2002.33426.
6
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study.
United European Gastroenterol J. 2016 Dec;4(6):784-793. doi: 10.1177/2050640615600116. Epub 2015 Aug 6.
7
Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.
Pharmacotherapy. 2017 Dec;37(12):1578-1585. doi: 10.1002/phar.2036. Epub 2017 Nov 21.
8
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU.
Aliment Pharmacol Ther. 2019 Feb;49(4):419-428. doi: 10.1111/apt.15114. Epub 2019 Jan 13.
9
Is there a therapeutic window of opportunity in early inflammatory bowel disease? Early stage inflammatory bowel disease: the actual management.
Minerva Gastroenterol Dietol. 2013 Sep;59(3):299-312.
10
Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.
Aliment Pharmacol Ther. 2001 Aug;15(8):1101-8. doi: 10.1046/j.1365-2036.2001.01023.x.
本文引用的文献
1
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Gut. 2007 Sep;56(9):1181-3. doi: 10.1136/gut.2006.115980.
2
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Gut. 2007 Sep;56(9):1226-31. doi: 10.1136/gut.2006.099978. Epub 2007 Jan 17.
3
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.
Aliment Pharmacol Ther. 2007 Jan 1;25(1):3-12. doi: 10.1111/j.1365-2036.2006.03134.x.
4
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248-54. doi: 10.1016/j.cgh.2006.06.025. Epub 2006 Aug 22.
Zotero 插件